| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $568,257 | 45 | 100 |
| Swanton Robert Charles | director | 0 | $0 | 1 | $872 | $-872 |
| Perry Jennifer Scott | Chief Operating Officer | 0 | $0 | 2 | $6,962 | $-6,962 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 0 | $0 | 8 | $25,513 | $-25,513 |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 0 | $0 | 8 | $54,508 | $-54,508 |
| Young Alethia | Chief Financial Officer | 0 | $0 | 4 | $56,038 | $-56,038 |
| Milnes Alistair | CHIEF OPERATING OFFICER | 0 | $0 | 6 | $77,320 | $-77,320 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER | 0 | $0 | 8 | $81,864 | $-81,864 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 0 | $0 | 8 | $265,181 | $-265,181 |
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $0 and sold $568,257 worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $4.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $7.67M was made by BAKER BROS. ADVISORS LP () on 2024‑12‑16.
| 2026-04-06 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 1,716 0.0026% | $5.05 | $8,666 | -3.48% | |
| 2026-04-06 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 525 0.0008% | $5.05 | $2,651 | -3.48% | |
| 2026-04-06 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 251 0.0004% | $5.05 | $1,268 | -3.48% | |
| 2026-04-06 | Sale | Perry Jennifer Scott | Chief Operating Officer | 370 0.0006% | $5.04 | $1,865 | -3.48% | |
| 2026-04-06 | Sale | Thompson Travis Alvin | Chief Financial Officer | 102 0.0002% | $5.05 | $515 | -3.48% | |
| 2026-04-02 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 5,967 0.0086% | $4.91 | $29,298 | -6.44% | |
| 2026-04-02 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 1,879 0.0027% | $4.91 | $9,226 | -6.44% | |
| 2026-04-02 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 1,521 0.0022% | $4.91 | $7,468 | -6.44% | |
| 2026-04-02 | Sale | Perry Jennifer Scott | Chief Operating Officer | 1,038 0.0015% | $4.91 | $5,097 | -6.44% | |
| 2026-04-02 | Sale | Thompson Travis Alvin | Chief Financial Officer | 799 0.0012% | $4.91 | $3,923 | -6.44% | |
| 2026-01-05 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 10,989 0.0155% | $6.46 | $70,989 | -23.75% | |
| 2026-01-05 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 3,266 0.0046% | $6.46 | $21,098 | -23.75% | |
| 2026-01-05 | Sale | Milnes Alistair | CHIEF OPERATING OFFICER | 3,416 0.0048% | $6.46 | $22,067 | -23.75% | |
| 2026-01-05 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2,367 0.0033% | $6.45 | $15,267 | -23.75% | |
| 2026-01-05 | Sale | Young Alethia | Chief Financial Officer | 4,334 0.0061% | $6.49 | $28,123 | -23.75% | |
| 2026-01-05 | Sale | Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 1,115 0.0016% | $6.45 | $7,192 | -23.75% | |
| 2026-01-02 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 10,325 0.0143% | $6.80 | $70,210 | -24.48% | |
| 2026-01-02 | Sale | Skynner Michael | CHIEF TECHNOLOGY OFFICER | 3,045 0.0042% | $6.80 | $20,706 | -24.48% | |
| 2026-01-02 | Sale | Milnes Alistair | CHIEF OPERATING OFFICER | 3,244 0.0045% | $6.80 | $22,059 | -24.48% | |
| 2026-01-02 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2,827 0.0039% | $6.80 | $19,224 | -24.48% |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 611313 0.8809% | $2.51M | 0 | 47 | |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER | 159562 0.2299% | $654,204.20 | 0 | 18 | |
| Milnes Alistair | CHIEF OPERATING OFFICER | 136717 0.197% | $560,539.70 | 0 | 16 | |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 96136 0.1385% | $394,157.60 | 0 | 13 | |
| Perry Jennifer Scott | Chief Operating Officer | 92464 0.1332% | $379,102.40 | 0 | 2 | |
| Young Alethia | Chief Financial Officer | 87081 0.1255% | $357,032.10 | 0 | 5 | |
| Thompson Travis Alvin | Chief Financial Officer | 65364 0.0942% | $267,992.40 | 0 | 18 | |
| Swanton Robert Charles | director | 15487 0.0223% | $63,496.70 | 0 | 1 | |
| BAKER BROS. ADVISORS LP | 9995274 14.4035% | $40.98M | 2 | 0 | <0.0001% | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 2.8215% | $8.03M | 1 | 0 | <0.0001% |
| HARLAND DEBORAH | director | 1915275 2.76% | $7.85M | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 2.7531% | $7.83M | 1 | 2 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 1875637 2.7029% | $7.69M | 1 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 1769641 2.5501% | $7.26M | 1 | 0 | <0.0001% |
| Anstey Michael | director | 1751437 2.5239% | $7.18M | 1 | 0 | <0.0001% |
| Cambridge Innovation Capital (Jersey) Ltd | 10 percent owner | 1751437 2.5239% | $7.18M | 1 | 0 | <0.0001% |
| NG CAROLYN | director | 571429 0.8234% | $2.34M | 1 | 0 | <0.0001% |
| Arroyo Santiago | CHIEF DEVELOPMENT OFFICER | 69057 0.0995% | $283,133.70 | 0 | 1 | |
| Keen Nicholas | CHIEF SCIENTIFIC OFFICER | 62024 0.0894% | $254,298.40 | 0 | 16 | |
| Crockett Nigel | CHIEF BUSINESS OFFICER | 51053 0.0736% | $209,317.30 | 0 | 13 | |
| BINGHAM KATE | director | 38708 0.0558% | $158,702.80 | 1 | 2 | <0.0001% |
| Smethurst Dominic | Chief Medical Officer | 36699 0.0529% | $150,465.90 | 0 | 1 | |
| Kalowski Lee | President and CFO | 30309 0.0437% | $124,266.90 | 0 | 13 | |
| Legault Pierre | director | 0 0% | $0 | 0 | 8 |
$9,340,232 | 98 | -5.71% | $278.78M | |
$5,911,307 | 70 | -1.38% | $273.1M | |
$17,468,215 | 46 | 18.85% | $294.2M | |
$64,573,910 | 36 | -14.02% | $290.38M | |
$41,505,594 | 29 | 21.51% | $277.96M | |
$79,019,806 | 27 | 7.24% | $308.08M | |
$3,668,031 | 23 | 2.05% | $315.18M | |
$38,821,584 | 20 | -2.17% | $254.89M | |
$1,447,973 | 17 | 13.95% | $308.17M | |
$104,137,421 | 15 | 21.28% | $290.45M | |
$10,399,379 | 13 | 13.60% | $267.22M | |
$6,385,840 | 12 | 0.69% | $278.67M | |
Bicycle Therapeutics plc (BCYC) | $112,952,085 | 11 | -19.19% | $284.52M |
$13,258,734 | 9 | 18.72% | $290.03M | |
$91,549,696 | 8 | -6.55% | $274.23M | |
$5,529,561 | 8 | 5.30% | $291.46M | |
$8,293,950 | 7 | 5.14% | $252.93M | |
$20,729,984 | 5 | 51.71% | $256.25M | |
$37,067 | 3 | -89.81% | $308.97M |
| Increased Positions | 56 | +51.38% | 5M | +13.28% |
| Decreased Positions | 43 | -39.45% | 4M | -10.52% |
| New Positions | 20 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 1M | Sold Out |
| Total Postitions | 122 | +11.93% | 39M | +2.76% |
| Baker Bros. Advisors Lp | $72,714.00 | 21.77% | 10.89M | 0 | 0% | 2025-09-30 |
| Fcpm Iii Services B.V. | $23,062.00 | 6.91% | 3.45M | 0 | 0% | 2025-09-30 |
| Armistice Capital, Llc | $19,893.00 | 5.96% | 2.98M | +178,000 | +6.36% | 2025-09-30 |
| Westfield Capital Management Co Lp | $19,723.00 | 5.91% | 2.95M | +172,052 | +6.19% | 2025-09-30 |
| Siren, L.L.C. | $13,445.00 | 4.03% | 2.01M | 0 | 0% | 2025-09-30 |
| Long Focus Capital Management, Llc | $9,477.00 | 2.84% | 1.42M | +101,402 | +7.7% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $9,250.00 | 2.77% | 1.38M | -83,599 | -5.69% | 2025-09-30 |
| Acadian Asset Management Llc | $8,781.00 | 2.63% | 1.31M | +616,055 | +88.2% | 2025-09-30 |
| Candriam S.C.A. | $7,832.00 | 2.35% | 1.17M | 0 | 0% | 2025-09-30 |
| Principal Financial Group Inc | $7,671.00 | 2.3% | 1.15M | +451,135 | +64.7% | 2025-09-30 |